Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 18/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 18/20 | 0.55 |
| ▸ | ITGAL | P20701 | 18/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20833731 | 1.00 | ITGB2 (0.55) | ITGB2ICAM1ITGALCYP2C9MAPT | |
| Hydrochloric Acid SCHEMBL31021044 | 0.99 | ITGB2 (0.55) | ITGB2ICAM1ITGALCYP2C9MAPT | |
| Hydrochloric Acid SCHEMBL28387762 | 0.99 | ITGB2 (0.55) | ITGB2ICAM1ITGALCYP2C9MAPT | |
| Hydrochloric Acid SCHEMBL29547703 | 0.91 | ITGB2 (0.55) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL14679326 | 0.91 | ITGB2 (0.46) | ITGB2ICAM1ITGALCYP2C9MAPT | |
| SCHEMBL24360217 | 0.91 | ITGB2 (0.54) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20903203 | 0.90 | ITGB2 (0.66) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL879313 | 0.90 | ITGB2 (0.66) | ITGB2ICAM1ITGALCYP2C9 | |
| Hydrochloric Acid SCHEMBL20680587 | 0.90 | ITGB2 (0.65) | ITGB2ICAM1ITGALCYP2C9 | |
| Hydrochloric Acid SCHEMBL20680588 | 0.90 | ITGB2 (0.65) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286250-B2 | Process for preparing and purifying a LFA-1 antagonist | INTERQUIM, S.A. (ES) | 2022-03-29 | — | — | US | disclosed |
| US-20210246123-A1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON S.P.A. (IT) | 2021-08-12 | — | — | US | disclosed |
| US-11001574-B2 | Process to obtain a tetrahydroisoquinoline derivative | MEDICHEM S.A. (ES) | 2021-05-11 | — | — | US | disclosed |
| EP-3658549-B1 | PROCESS FOR PREPARING AND PURIFYING THE LFA-1 ANTAGONIST LIFITEGRAST | INTERQUIM SA (ES) | 2021-05-05 | — | — | EP | disclosed |
| US-20200369651-A1 | A PROCESS TO OBTAIN A TETRAHYDROISOQUINOLINE DERIVATIVE | MEDICHEM, S.A. (ES) | 2020-11-26 | — | — | US | disclosed |
| US-20200277282-A1 | PROCESS FOR PREPARING AND PURIFYING A LFA-1 ANTAGONIST | INTERQUIM, S.A. (ES) | 2020-09-03 | — | — | US | disclosed |
| WO-2019053607-A1 | PROCESS FOR PREPARATION OF LIFITEGRAST | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019043724-A1 | PROCESSES FOR THE PREPARATION OF (S)-2-(2-(BENZOFURAN-6-CARBONYL)-5,7-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBOXAMIDO)-3-(3-(METHYLSULFONYL)PHENYL) PROPANOIC ACID AND POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019020580-A1 | PROCESS FOR PREPARING AND PURIFYING THE LFA-1 ANTAGONIST LIFITEGRAST | INTERQUIM, S.A. (ES) | 2019-01-31 | — | — | WO | disclosed |
| WO-2019004936-A1 | PROCESS FOR PREPARING LIFITEGRAST AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (TW) | 2019-01-03 | — | — | WO | disclosed |
| US-20160368902-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | SARCODE BIOSCIENCE INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-8080562-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20090298869-A1 | Crystalline pharmaceutical and methods of preparation and use thereof | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369651-A1 | A PROCESS TO OBTAIN A TETRAHYDROISOQUINOLINE DERIVATIVE | LMTK2, CYP11B2, KCNQ5 | ITGB2 3633/4885ICAM1 4733/4885ITGAL 3195/4885 |
| US-20160368902-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-11286250-B2 | Process for preparing and purifying a LFA-1 antagonist | LIFR, ITGA1, ITGAL | ITGB2 13/4885ICAM1 75/4885ITGAL 3/4885 |
| US-20200277282-A1 | PROCESS FOR PREPARING AND PURIFYING A LFA-1 ANTAGONIST | LIFR, ITGA1, ITGAL | ITGB2 13/4885ICAM1 75/4885ITGAL 3/4885 |
| US-20090298869-A1 | Crystalline pharmaceutical and methods of preparation and use thereof | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-20210246123-A1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | LIFR, FLT3, F12 | ITGB2 908/4885ICAM1 4588/4885ITGAL 590/4885 |
| US-11001574-B2 | Process to obtain a tetrahydroisoquinoline derivative | KCNQ5, KCNQ4, KCNQ2 | ITGB2 3390/4885ICAM1 4655/4885ITGAL 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.